-

02:13:35 AM

SAVA Stock News

SAVA - Cassava Sciences Inc

10/06/21 8:30 AM

Nasdaq : SAVA

clinical trial

Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease

First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s Disease A Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimer’s Disease AUSTIN, Texas, Oct. 06, 2021

RHEA-AI

neutral

09/22/21 8:30 AM

Nasdaq : SAVA

Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease

Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12 No Behavior Disorders on NPI in Over 50% Of Study Subjects at Month 12 Initiation of Pivotal Phase 3 Clinical Program Remains

RHEA-AI

neutral

09/09/21 8:15 AM

Nasdaq : SAVA

conferences

Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23 rd Annual Global Investment Conference, a virtual event that takes

RHEA-AI

neutral

09/03/21 7:00 AM

Nasdaq : SAVA

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a public statement regarding recent allegations made against the Company. “Let me be very clear: I think these allegations are false,”

RHEA-AI

very negative

08/27/21 11:31 AM

Nasdaq : SAVA

clinical trial

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with

RHEA-AI

neutral

08/25/21 6:00 AM

Nasdaq : SAVA

Cassava Sciences Responds to Allegations

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding

RHEA-AI

neutral

08/24/21 8:15 AM

Nasdaq : SAVA

clinical trial

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a

RHEA-AI

neutral

08/03/21 8:30 AM

Nasdaq : SAVA

earnings

Cassava Sciences Reports Second Quarter 2021 Financial Results

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2021. Net loss for the

RHEA-AI

very positive

08/02/21 7:54 PM

Nasdaq : SAVA

earnings

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the

RHEA-AI

neutral

07/29/21 9:53 AM

Nasdaq : SAVA

Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease

Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 Months Robust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p< 0.00001) Biomarker Improvements Track with Cognitive Improvements Oral Presentation at AAIC Today

RHEA-AI

very positive